The Pharma Letter1h
Merck KGaA ‘back on the growth path’
Germany’s Merck KGaA (MRK: DE) returned to profitable growth in 2024 and delivered on its guidance for the year.
Piper Sandler Keeps Their Hold Rating on Halozyme (HALO)
Piper Sandler analyst Joseph Catanzaro maintained a Hold rating on Halozyme (HALO – Research Report) today and set a price target of $53.00.
Le Lézard5h
Merck & Co., Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - MRK
The Gross Law Firm issues the following notice to shareholders of Merck & Co., Inc. . Shareholders who purchased shares of MRK ...
Merck KGaA (ETR:MRK) shareholders have earned a 8.1% CAGR over the last five years
For example, the Merck KGaA (ETR:MRK) share price is up 39% in the last five years, slightly above the market return. In comparison, the share price is down 13% in a year. So let's assess the ...
Investing Snacks8h
Merck’s Keytruda Injection Faces Patent Battle With Halozyme
Merck’s push to make Keytruda injectable has triggered a patent dispute with Halozyme. The conflict arises over the use of ...
Merck & Co. (MRK): An Undervalued Wide Moat Stock to Buy According to Analysts
We recently compiled a list of the 12 Undervalued Wide Moat Stocks to Buy According to Analysts. In this article, we are ...